ANTIVIRAL ACTIVITY OF FAVIPIRAVIR AGAINST NOVEL DELTA AND OMICRON SARS-COV-2 VARIANTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate the antiviral activity of favipiravir against different SARS- CoV-2 variants. Materials and methods. The antiviral activity of the drug against three SARS-CoV-2 variants, such as the strains B.1.1, delta, and omicron, in Vero cells was investigated in vitro. The results were assessed from the reduced viral RNA yield in the infected cells by a real-time reverse transcription PCR assay. Results. Favipiravir effectively inhibited the reproduction of SARS-CoV-2, while the inhibitory concentration of EC50 of the drug did not substantially differ between the virus variants within a range of 200-300 ßM for all the strains. Conclusion. Evolutionary changes in the SARS- CoV-2 virus did not have a significant impact on the in vitro activity of the drug, which is maintained against novel SARS-CoV-2 variants.

Full Text

Restricted Access

About the authors

Kirill L. KRYSHEN

Research and Production Association «Dom Farmatsii» (House of Pharmacy)

Email: kryshen.kl@doclinika.ru
Head, Department of Specific Toxicology and Microbiology Leningrad Region, Russia

Viktor P. VOLOK

M.P. Chumakov Federal Research Center for Testing and Designing Immunobiologicals Russian Academy of Sciences

Email: volok_vp@chumakovs.su
Junior Researcher, Laboratory of Poliomyelitis and Other Enteroviral Infections with the WHO Reference Center for Poliomyelitis Surveillance, Department of Actual and Re-Emerging Infections with Pandemic Potential, (Institute of Poliomyelitis) Moscow, Russia

Elena Yu. SHUSTOVA

M.P. Chumakov Federal Research Center for Testing and Designing Immunobiologicals Russian Academy of Sciences

Email: shustova_eu@chumakovs.su
Researcher, Laboratory of Poliomyelitis and Other Enteroviral Infections with the WHO Reference Center for Poliomyelitis Surveillance, Department of Actual and Re-Emerging Infections with Pandemic Potential, (Institute of Poliomyelitis) Moscow, Russia

Georgi A. SHIPUNOV

AO «R-Farm»

Email: shipunov@rpharm.ru
Specialist, Department of Preclinical Tests Moscow, Russia

A. V ZINCHENKO

AO «R-Farm»

Moscow, Russia

Mikhail Yu. SAMSONOV

AO «R-Farm»

Email: shipunov@rpharm.ru
Cand. Med. Sci., Medical Director Moscow, Russia

Olga V. FILON

AO «R-Farm»

Email: ov.filon@rpharm.ru
Director, Department for Preclinical and Clinical Development Moscow, Russia

Elena V. SHIPAEVA

AO «R-Farm»

Email: shipaeva@rpharm.ru
Cand. Med. Sci., Head, Department of Preclincal Tests Moscow, Russia

References

  1. Kupriyanov S.V., Semenova Y.V., Semenova L.M. New Coronavirus Infection. Today’S View of the Pandemic. Acta medica Eurasica 2021; (3): 48-59. doi: 10.47026/2413-4864-2021-3-48-59
  2. Sangawa H., Komeno T., Nishikawa H., Yoshida A., Takahashi K., Nomura N. et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 2013; 57(11): 5202-8.
  3. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5’-triphosphate towards influenza A virus polymerase. PLoS One 2013; 8(7): e68347.
  4. Baranovich T., Wong S.-S., Armstrong J., Marjuki H., Webby R.J,. Webster R.G. et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 2013; 87(7): 3741-51.
  5. Escribano-Romero E., Jiménez de Oya N., Domingo E., Saiz J.C. Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis. Antimicrob. Agents Chemother. 2017; 61(11): e01400-17. doi: 10.1128/AAC.01400-17
  6. de Âvila A.I., Gallego I., Soria M.E., Gregori J., Quer J., Esteban J.I. et al. Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One 2016; 11(10): e0164691-e016461. https://pubmed.ncbi.nlm.nih.gov/27755573
  7. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 2009; 53(1): 202-9.
  8. Gowen B.B., Wong M.-H., Jung K.-H., Sanders A.B., Mendenhall M., Bailey K.W. et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 2007; 51(9): 3168-76.
  9. Mendenhall M., Russell A., Juelich T., Messina.EL., Smee D.F., Freiberg A.N. et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 2011; 55(2): 782-7.
  10. Rocha-Pereira J., Jochmans D., Dallmeier K., Leyssen P., Nascimento M.S.J., Neyts J. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res.Commun. 2012; 424(4): 777-80.
  11. Shannon A., Selisko B., Le N.-TT., Huchting J., Touret F., Piorkowski G. et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat.Commun. 2020; 11(1): 4682. https://doi.org/10.1038/s41467-020-18463-z
  12. Driouich J.-S, Cochin M., Lingas G., Moureau G., Touret F., Petit P.-R. et al. Favipiravir antiviral efficacy against SARS- CoV-2 in a hamster model. Nat.Commun. 2021; 12(1): 1735. https://doi.org/10.1038/s41467-021-21992-w
  13. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-71. https://doi.org/10.1038/s41422-020-0282-0
  14. Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S. et al. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob. Agents Chemother. 2020; 64(7): e00819-20. doi: 10.1128/AAC.00819-20
  15. Kaptein S.J.F., Jacobs S., Langendries L., Seldeslachts L., Ter Horst S., Liesenborghs L. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Nat. Acad. Sci. USA 2020; 117(43): 26955-65. doi: 10.1073/pnas.2014441117
  16. Ruzhentsova T.A., Oseshnyuk R.A., Soluyanova T.N., Dmitrikova E.P., Mustafaev D.M., Pokrovskiy K.A. et al. Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19. Am. J. Transl. Res. 2021; 13(11): 12575-87. https://pubmed.ncbi.nlm.nih.gov/34956474
  17. Ivashchenko A.A., Dmitriev K.A., Vostokova N.V., Azarova V.N., Blinow A.A., Egorova A.N. et al. Avifavir for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am. 2021; 73(3): 531-4. doi: 10.1093/cid/ciaa1176
  18. Shinkai M., Tsushima K., Tanaka S., Hagiwara E., Tarumoto N., Kawada I. et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III. Clinical Trial. Infect. Dis. Ther. 2021; 10(4): 2489-509. doi: 10.1007/s40121-021-00517-4
  19. Manabe T., Kambayashi D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 2021; 21(1): 489. doi: 10.1186/s12879-021-06164-x
  20. Hassanipour S., Arab-Zozani M., Amani B., Heidarzad F., Fathalipour M., Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep. 2021; 11(1): 11022. doi: 10.1038/s41598-021-90551-6
  21. Finberg R.W., Ashraf M., Julg B., Ayoade F., Marathe J.G., Issa N.C. et al. US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19. Open. Forum Infect Dis. 2021; 8(12): 563. doi: 10.1093/ofid/ofab563
  22. Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». М., 2021; версия 14. 233 с. https://base.garant.ru/403310712/?
  23. Ömeroglu Ş.K., Temel F., Altun D., Öztop B. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19. Turkish J. Med. Sci. 2021; 51(6): 2827-34. doi: 10.3906/sag-2101-146
  24. Bosaeed M., Alharbi A., Mahmoud E., Alrehily S., Bahlaq M., Gaifer Z. et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebocontrolled clinical trial. Clin. Microbiol. Infect. 2022. https://www.sciencedirect.com/science/article/pii/S1198743X21007345
  25. https://www.appilitherapeutics.com/newsfeed/Appili-Therapeutics-Provides-Update-on-Phase-3-PRESECO-Clinical-Trial-Evaluating-Avigan%C2% AE%2FReeqonus%E2%84%A2
  26. Solaymani-Dodaran M., Ghanei M., Bagheri M., Qazvini A., Vahedi E., Hassan Saadat S. et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.Int Immunopharmacol. 2021; 95: 107522. doi: 10.1016/j.intimp.2021.107522
  27. Case J.B., Bailey A.L., Kim A.S., Chen R.E., Diamond M.S. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology 2020; 548: 39-48. https://pubmed.ncbi.nlm.nih.gov/32838945
  28. Jureka A.S., Silvas J.A., Basler C.F. Propagation, Inactivation, and Safety Testing of SARS-CoV-2. Viruses 2020; 12(6): 622 doi: 10.3390/v12060622
  29. Bojkova D., Widera M., Ciesek S., Wass M.N., Michaelis M., Cinatl J. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022. https://doi.org/10.1038/s41422-022-00619-9
  30. Tomita Y., Takeda M., Matsuyama S. The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells. Antimicrobial agents and chemotherapy. 2021; 65: e00020-21 doi: 10.1128/AAC.00020-21
  31. Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M. et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New Engl. J. Med. 2022. 386(10): 995-8. doi: 10.1056/NEJMc2119407
  32. Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J. et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022; 198: 105252. doi: 10.1016/j. antiviral.2022.105252
  33. Wang Y., Zhong W., Salam A., Tarning J., Zhan Q., Huang J.-A. et al. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine 2020; 62: 103125. http://europepmc.org/abstract/ MED/33232871
  34. Irie K., Nakagawa A., Fujita H., Tamura R., Eto M., Ikesue H. et al. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. Clin. Trans. Sci. 2020; 13(5): 880-5. doi: 10.1111/ cts.12827
  35. Du Y.-X., Chen X.-P. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin. Pharmacol. Ther. 2020; 108(2): 242-7. doi: 10.1002/cpt.1844
  36. Arshad U., Pertinez H., Box H., Tatham L., Rajoli R.K.R., Curley P. et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin. Pharmacol. Ther. 2020; 108(4): 775-90. doi: 10.1002/cpt.1909
  37. Pertinez H., Rajoli K.R., Khoo S.H., Owen A. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5’-triphosphate exposure to support posology for SARS-CoV-2. J. Antimicrob. Chemother. 2021; 76 (Suppl 1). doi: 10.1093/jac/ dkab135

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies